EuropaBio is pleased to host its third Summit focused on biotechnology & biomanufacturing.
Biotechnology is a critical technology for Europe. Delivery of innovation into market drives competitiveness, security, supply chain resilience plus societal and environmental goals. Europe must be ambitious and globally aware, with a focus on securing its biotechnology capability within fast changing global geopolitics.
The current Commission has a significant opportunity to set and deliver on the ambition needed. Legislation such as the Biotech Act, plus the frameworks that we create for sectors including health, agri-food and manufacturing.
The half day Summit brings together EuropaBio Members and stakeholders to understand the ambition needed for legislation, how the EU and its Member States can deliver and recognition of global positioning needed.
It is supported by biotech product displays and EU projects, plus evening networking reception. It will be followed by a Summit Statement and public webinar hosted in November.
Agenda:
| 12:30 Registration and lunch |
| 13:15 Welcome and Keynote session Summit keynotes bring Industry, Parliament and Commission perspectives to Europe’s ambition for biotech and biomanufacturing and the policy framework currently in action. Commissioner Olivér Várhelyi – Commissioner for Health and Animal Welfare Markus Staempfli – EuropaBio Chair, Vice President Europe Major Markets & Canada, CSL Behring MEP Stine Bosse – MEP and co-chair EU Alliance of Biotech and Life Sciences |
| 14:00 Panel sessions The current legislative cluster impacting biotechnology and biomanufacturing is in focus for our panel discussions. Stakeholders from across industry, policy and member states discuss what Europe’s ambition must be and how individual and aligned legislations can deliver. |
| Panel 1 – Enabling EU markets How policy creates markets for biotech products and enables biomanufacturing processes. |
| Panel 2 – Enhancing access How market pathways are vital for product and process commercial viability, determining speed and scale of access and uptake. |
| Panel 3 – Building the EU ecosystem How knowledge, skills, finance and infrastructure deliver on market potential for Europe. |
| 17:50 Pre-reception remarks |
| 18:00 Reception |
| 20:30 Close |
This event will be accessible by invitation only, for more information contact us at: communications@europabio.org and c.skentelbery@europabio.org
The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.
Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.
Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.
Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.
Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.
Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.